PTC Therapeutics, Inc. — 2017 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2017, PTC was a commercial-stage biopharmaceutical company focused on rare diseases. Its principal marketed products were Translarna for nonsense-mutation Duchenne muscular dystrophy (nmDMD), available outside the United States, and Emflaza for Duchenne muscular dystrophy (DMD), launched in the United States in 2017. The filing compares 2017 with 2016 and 2015; selected quarterly data are also provided.
Financial performance and liquidity
| Metric | 2017 | 2016 | Change or context |
|---|---|---|---|
| Total revenue | $194.4 million | $82.7 million | Up $111.7 million; product revenue rose to $174.1 million from $81.4 million. |
| Translarna net sales | $145.2 million | $81.4 million | Growth reflected existing markets and geographic expansion. |
| Emflaza net sales | $28.8 million | Not marketed | U.S. launch began in May 2017. |
| Collaboration and grant revenue | $20.3 million | $1.3 million | Primarily included a $20 million Roche milestone for the SMA program. |
| Operating expenses | $258.7 million | $214.8 million | Included $15.4 million amortization of acquired Emflaza rights; SG&A increased 25% to $121.3 million. |
| Loss from operations | $64.3 million | $132.1 million | Operating loss narrowed. |
| Net loss | $79.0 million | $142.1 million | Basic and diluted loss per share was $2.02, versus $4.17. |
| Operating cash flow | $(10.1) million | $(103.6) million | Cash use improved substantially. |
| Cash, cash equivalents and marketable securities | $191.2 million | $231.7 million | Year-end working capital was $167.0 million. |
| Long-term debt, carrying value | $145.0 million | $98.2 million | Increase included $40 million drawn under the MidCap secured facility. |
The filing does not present a single headline gross-margin measure. Product cost comparisons are affected by Translarna manufacturing costs that had been expensed as R&D before 2017. PTC reported an accumulated deficit of $814.1 million and expected operating losses to continue through 2018. Management said available cash, product cash flows and financing resources were expected to fund operations and capital needs for at least 12 months, subject to assumptions that could prove incorrect.
Material changes versus the prior period
- Revenue more than doubled, supported by continued Translarna growth, the Emflaza U.S. launch, and the Roche milestone.
- R&D expense was essentially flat at $117.5 million. SG&A rose by $24.1 million, mainly from additional personnel, Emflaza launch and commercial support, and Translarna marketing.
- PTC acquired all Emflaza rights in April 2017 for $75 million cash and 6,683,598 common shares. The acquired rights were recorded as an intangible asset and amortized over an estimated seven-year useful life.
- Cash and marketable securities declined by $40.4 million; financing included a $40 million MidCap borrowing. Shares outstanding increased from 34.2 million at year-end 2016 to 41.6 million at year-end 2017, largely reflecting the Emflaza acquisition.
- In the fourth quarter, PTC reported $20.1 million of collaboration and grant revenue, $5.5 million of operating income and $1.3 million of net income, principally reflecting the Roche milestone.
Outlook, risks, contingencies and unusual items
- Translarna regulatory dependence: EEA authorization remained conditional, subject to annual renewal and Study 041 results due by the end of the third quarter of 2021. The FDA issued a Complete Response Letter in October 2017 and denied PTC’s appeal in February 2018. The FDA suggested a possible accelerated-approval path requiring new dystrophin-production data; PTC intended to pursue it, but approval and agreement on study methods were uncertain.
- Clinical evidence risk: The primary efficacy endpoint in the Phase 3 ACT DMD trial was not statistically significant in the overall intent-to-treat population. Favorable subgroup and meta-analysis findings included nominal, post-hoc or retrospective analyses, which regulators may give less weight. Study 041 enrollment, cost, timing and outcome could affect EEA authorization and sales.
- Commercial and pricing risk: Revenue depends on reimbursement, acceptable pricing, patient identification and continued market access. Translarna’s German commercial listing had been discontinued over pricing; access relied in part on reimbursed imports. Emflaza faced payor coverage, prior-authorization and pricing scrutiny.
- Product concentration and pipeline: The two DMD products drove 2017 product sales. Translarna development for nmCF was discontinued after ACT CF did not meet its primary or secondary endpoints; nmMPS I enrollment was stopped because eligible patients were difficult to identify. SMA studies of RG7916, and Translarna studies in aniridia and Dravet syndrome/CDKL5, remained in development. Oncology candidate PTC596 had completed Phase 1, with reformulation and further development anticipated.
- Debt and funding: The $60 million MidCap facility had $40 million drawn; the remaining $20 million depended on achieving trailing-12-month net product revenue of at least $120 million by December 31, 2018. The facility bears interest at LIBOR, subject to a 1% floor, plus 6.15%, and is secured by specified assets, including intellectual property. The $150 million principal amount of 3.00% convertible notes is due in 2022. PTC disclosed compliance with MidCap covenants at year-end.
- Contingencies and unusual items: A securities class action settlement was agreed in principle, subject to court approval, and was expected to be funded by insurance subject to the deductible; PTC accrued $0.5 million for the remaining deductible. Related derivative lawsuits were also pending. The filing said resolution was not expected to materially affect consolidated financial position or liquidity, but could affect results in an individual period.
- Other financial considerations: PTC recorded a full valuation allowance against net deferred tax assets. Federal NOL use is subject to ownership-change limitations, and the 2017 tax law’s effects were not considered material to the 2017 statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Progress, enrollment and endpoint performance of Study 041, and the timing and outcome of annual EEA authorization renewals.
- Whether PTC and the FDA agree on dystrophin-data methods, and whether new data support an NDA resubmission or accelerated approval.
- Product-level sales, payer coverage, realized pricing, rebates and receivables—especially the sustainability of Translarna access and Emflaza adoption.
- Cash runway and operating cash use as commercialization, clinical-trial and post-marketing costs continue; also verify eligibility for the undrawn $20 million MidCap tranche.
- Debt service, secured-lender covenants, Emflaza-related contingent payments and supply obligations, and potential dilution from shares, options and convertible notes.
- Final court approval and insurance coverage for the securities settlement, as well as developments in the derivative actions.